Moderna (MRNA) closed at $18.92 in the latest trading session, marking a +0.05% move from the prior day. This move lagged the S&P 500's daily gain of 0.47%. At the same time, the Dow added 0.4%, and the tech-heavy Nasdaq gained 0.87%.
Coming into today, shares of the biotechnology company had lost 9.69% in the past month. In that same time, the Medical sector lost 0.39%, while the S&P 500 gained 1.43%.
Wall Street will be looking for positivity from MRNA as it approaches its next earnings report date. This is expected to be February 26, 2020.
It is also important to note the recent changes to analyst estimates for MRNA. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. MRNA currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
Moderna (MRNA) Gains But Lags Market: What You Should Know
Moderna (MRNA) closed at $18.92 in the latest trading session, marking a +0.05% move from the prior day. This move lagged the S&P 500's daily gain of 0.47%. At the same time, the Dow added 0.4%, and the tech-heavy Nasdaq gained 0.87%.
Coming into today, shares of the biotechnology company had lost 9.69% in the past month. In that same time, the Medical sector lost 0.39%, while the S&P 500 gained 1.43%.
Wall Street will be looking for positivity from MRNA as it approaches its next earnings report date. This is expected to be February 26, 2020.
It is also important to note the recent changes to analyst estimates for MRNA. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. MRNA currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 81, which puts it in the top 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.